Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,900,424

« Back to Dashboard
Patent 5,900,424 protects NEXIUM, VIMOVO, and NEXIUM 24HR, and is included in six NDAs. There have been zero Paragraph IV challenges on Vimovo and Nexium There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for NEXIUM has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-one patent family members in thirty-eight countries.

Summary for Patent: 5,900,424

Title: Omeprazole magnesium salt form
Abstract:A novel compound form of magnesium omeprazole useful in the manufacture of pharmaceutical formulations, the use of the product and the process for its production are described.
Inventor(s): Kallstrom; Lars .ANG.ke (Sodertalje, SE), Nygren; Monica Annelie (Sodertalje, SE)
Assignee: Astra Aktiebolag (Sodertalje, SE)
Application Number:08/313,342
Patent Claim Types:
see list of patent claims
Compound; Process; Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
esomeprazole magnesium
FOR SUSPENSION, DELAYED RELEASE;ORAL022101-001Feb 27, 2008RXNoNo5,900,424*PED► subscribe
Horizon Pharma Usa
esomeprazole magnesium; naproxen
TABLET, DELAYED RELEASE;ORAL022511-002Apr 30, 2010RXYesNo5,900,424*PED► subscribe
Horizon Pharma Usa
esomeprazole magnesium; naproxen
TABLET, DELAYED RELEASE;ORAL022511-001Apr 30, 2010RXYesYes5,900,424*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,900,424

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9302396Jul 09, 1993
PCT Information
PCT FiledJuly 08, 1994PCT Application Number:PCT/SE94/00680
PCT Publication Date:January 19, 1995PCT Publication Number: WO95/01977

International Patent Family for Patent: 5,900,424

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany69429774► subscribe
Denmark0707580► subscribe
Algeria1792► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.